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Objectives
To report the baseline results of a longitudinal psychosocial
study that forms part of the IMPACT study, a multi-national
investigation of targeted prostate cancer (PCa) screening
among men with a known pathogenic germline mutation in
the BRCA1 or BRCA2 genes.
Particpants and Methods
Men enrolled in the IMPACT study were invited to
complete a questionnaire at collaborating sites prior to
each annual screening visit. The questionnaire included
sociodemographic characteristics and the following
measures: the Hospital Anxiety and Depression Scale
(HADS), Impact of Event Scale (IES), 36-item short-form
health survey (SF-36), Memorial Anxiety Scale for Prostate
Cancer, Cancer Worry Scale-Revised, risk perception and
knowledge. The results of the baseline questionnaire are
presented.
Results
A total of 432 men completed questionnaires: 98 and 160 had
mutations in BRCA1 and BRCA2 genes, respectively, and 174
were controls (familial mutation negative). Participants’
perception of PCa risk was influenced by genetic status.
Knowledge levels were high and unrelated to genetic status.
Mean scores for the HADS and SF-36 were within reported
general population norms and mean IES scores were within
normal range. IES mean intrusion and avoidance scores were
significantly higher in BRCA1/BRCA2 carriers than in controls
and were higher in men with increased PCa risk perception.
At the multivariate level, risk perception contributed more
significantly to variance in IES scores than genetic status.
Conclusion
This is the first study to report the psychosocial profile of men
with BRCA1/BRCA2 mutations undergoing PCa screening. No
clinically concerning levels of general or cancer-specific distress
or poor quality of life were detected in the cohort as a whole. A
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small subset of participants reported higher levels of distress,
suggesting the need for healthcare professionals offering PCa
screening to identify these risk factors and offer additional
information and support to men seeking PCa screening.
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Introduction
Prostate cancer (PCa) is the most common non-melanoma
tumour in men worldwide, with an estimated 1.1 million men
diagnosed with PCa in 2012 [1]. Men with germline BRCA1
or BRCA2 gene mutations are known to be at an increased
risk of PCa. This risk is estimated to be 1.8–3.75-fold and
2.5–8.6-fold increased by the age of 65 years for BRCA1 and
BRCA2 mutation carriers, respectively [2,3]. Whilst there is
some debate about whether there is a true increased risk of
PCa for BRCA1 mutation carriers, there is solid evidence that
BRCA2 mutation carriers present at a younger age and with
aggressive disease [4,5]; therefore, prostate screening and early
detection could have an important role in reducing the
disease burden, particularly among BRCA2 mutation carriers
[6].
There is controversy about PCa screening using PSA testing
in the general population and the benefits and harms of
screening have been widely debated [7]. The US Prevention
Services Task Force currently recommends shared decision-
making for screening healthy men aged 55–69 years [7,8].
Additionally, PCa treatments have significant long-term side
effects that can have an impact on masculine identity,
physical and psychosocial symptoms and health-related
quality of life (HRQoL). Research is therefore needed to
identify targeted screening tools that can improve the benefit
to harm ratio for PCa screening.
The limited number of studies evaluating men with a family
history of PCa have generally supported the use of screening
in this population [9–12]. To our knowledge, no studies, to
date, have prospectively evaluated a PCa screening
programme for BRCA1/2 mutation carriers. The IMPACT
study (Identification of Men with a genetic predisposition to
ProstAte Cancer: Targeted Screening in men at higher genetic
risk and controls) is an international, multicentre study
evaluating the role of targeted PSA screening in men with
BRCA1/2 mutations [6].
Evidence supports the theory that genetic testing for BRCA1
and BRCA2 mutations does not have a significant long-term
psychological impact on most people tested [13,14]. Studies in
men undergoing PCa screening suggest that a minority
experience some anxiety, usually while waiting for results
[15–17]. Risk factors for anxiety include having a family
history of PCa, symptoms or abnormal genetic test results
[15–17]. As BRCA1/BRCA2 mutations confer an increased
disease risk and psychological distress [18], it is possible that
higher levels of anxiety may exist in people with this
mutation; however, risk perception has been shown not to
reflect true risk in both men with and without a family
history of PCa. It has also been reported that cancer worry is
high in men with a family history of PCa, with the number
of relatives dying from the disease predicting level of worry
[18]; however, a low level of PCa worry has also been
reported in men with a close relative with PCa [19].
Many issues arise when counselling men with BRCA1/BRCA2
mutations, and many factors affect the way in which men
react to and use information about their genetic status and
risk of developing cancer [20–22]. So far, there have been few
investigations either into the HRQoL impact for a man with a
BRCA1/BRCA2 mutation living with an increased risk of PCa,
or in those men who have gone on to develop PCa [23].
Several studies have confirmed the feasibility of collecting
HRQoL and psychosocial data as part of large PCa screening
trials [16,24–28].
In the present study, we report the baseline results of a
longitudinal HRQoL investigation carried out as part of the
IMPACT study. The specific aims of the study were to
evaluate the baseline psychosocial profile of men in the
IMPACT study and to identify possible predictors of high
levels of psychological distress or poor HRQoL.
Participants and Methods
Study Sample and Procedures
The IMPACT study recruited men from families with BRCA1
or BRCA2 mutations, with or without the familial mutation,
to a programme of annual PCa screening via PSA testing, for
a minimum of 5 years. The IMPACT study opened in 2005
and screening will end in 2019. The full design and methods
of the IMPACT study have previously been reported [6]. The
IMPACT study protocol was approved by the West Midlands
Research and Ethics Committee in the UK (reference 05/
MRE07/25) and subsequently by each participating
institution’s local ethics committee.
All men eligible for IMPACT were also eligible for the
HRQoL study. Men were eligible for participation if they
tested either positive, negative or were at 50% risk of
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inheriting the familial BRCA1/BRCA2 mutation and were
aged 40–69 years. Men who tested negative for their familial
mutation constituted the control group. Men were excluded if
they were known to have PCa at enrolment or if they had
another cancer with a prognosis of <5 years survival.
The HRQoL study was added to the IMPACT study protocol
in 2009. All sites were invited to participate in this sub-study.
Men enrolled in the IMPACT study at participating sites
were approached by letter prior to their next scheduled study
appointment inviting them to take part in the HRQoL study.
The HRQoL study involves completing a set of questionnaires
annually for 5 years, with each assessment taking place prior
to the annual PSA test. Men were sent the questionnaires
~4 weeks before their appointment and asked to post it back
or bring the completed questionnaire to their appointment.
Men were split into two cohorts: (i) a prospective arm, which
included men who joined the HRQoL study before their first
PSA screening within the IMPACT study; and (ii) a truncated
prospective arm, which included men already enrolled in the
IMPACT study before joining the HRQoL study. The total
target sample was a minimum of 300 men in each arm. In
the present analysis, we report the results of the baseline
questionnaires in the prospective (not truncated) cohort.
Study Measures
Psychological Distress
Distress was assessed using the Hospital Anxiety and Depression
Scale (HADS), the Impact of Event Scale (IES), the Cancer
Worry Scale-Revised (CWS-R), and the Memorial Anxiety Scale
for Prostate Cancer (MAX-PC). The HADS contains two sub-
scales of seven items that measure the presence and severity of
general anxiety and depression [29]. Each subscale generates a
score ranging from 0 to 21, and a score of >10 indicates clinically
relevant levels of anxiety or depression.
The IES is a 15-item scale measuring PCa-specific distress
through the frequency of intrusive or avoidant thoughts about
PCa [30]. Total scores on the intrusion and avoidance scales
range from 0–35 to 0–40, respectively. A higher score
indicates more frequent intrusive/avoidant thoughts about
risk of cancer; a score of >8.5 indicates clinically relevant
levels of distress.
The CWS-R is a six-item scale that measures worry about the
risk of developing cancer and the frequency and impact of
that worry on mood and daily functioning [31,32]. The CWS-
R uses a score of 1 (no worry) to 4 (maximum worry), giving
a summative score between 4 and 24. A high score indicates
greater worry, but no clinical thresholds for the scores are
available.
The MAX-PC includes three scales assessing PCa anxiety,
PSA anxiety, and fear of recurrence. In the present study, we
used the PCa anxiety (11 items) and PSA anxiety (3 items)
scales [33]. The PCa anxiety scale is scored from 0 to 33 and
the PSA anxiety scale from 0 to 9, with a higher score
indicating higher anxiety levels.
Health-Related Quality of Life
We assessed HRQoL using the 36-item short-form health
survey (SF-36) version 2.0 [34,35]. This questionnaire consists
of eight subscales: physical functioning; social functioning;
role limitations attributable to physical problems; role
limitations attributable to emotional problems; mental health;
vitality; pain; and general health. Summary scores are
calculated for two broad areas of subjective well-being:
physical health and mental health. All scales are linearly
converted to a 0–100 scale, with a higher score representing
better functioning.
Risk Perception
Men were asked to rate their perceived risk of PCa compared
with the average man’s risk: lower; the same; slightly
increased; moderately increased; or strongly increased [36].
Knowledge
We developed a ‘knowledge’ questionnaire based on a measure
developed by Lerman et al. [37] and Wonderlick and Fine
[38]. The nine true/false items (Fig. 1) assessed knowledge of
inheritance of BRCA1/BRCA2, the effect of having an altered
gene, and risk of PCa. Knowledge scores were created by
taking the sum of the correct responses to the nine items.
The internal consistency reliability, as assessed by Cronbach’s
coefficient a, was high for all measures used, ranging from
0.79 for the SF-36 General Health scale to 0.96 for the SF-36
Role Physical scale. Fourteen of the 15 scales had an a
coefficient >0.80.
Statistical Analysis
The dataset contained a small amount of missing data. For all
scales, except the SF-36, if ≥75% of a subscale was complete
then a total score (corrected for the total number of
questions) was calculated. If <75% was completed, data were
excluded. For the SF-36 score, scales were excluded when
there was <50% of a sub-scale completed, as per the
recommendation of the scale’s authors [39]. Ten percent of
the data entered were double-checked for coding accuracy
and completeness, and no errors were identified.
The SPSS 22.0 statistical computer package (SPSS Inc.,
Chicago, IL, USA) was used to manage and analyse the data.
Scores for each questionnaire were calculated in accordance
with each scale’s scoring system. Descriptive statistics,
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including means and standard deviations, were used to
summarize the sample characteristics and questionnaire data.
All psychometric scales (HADS, IES, SF-36, MAX-PC and
CWS-R) were skewed towards better scores. Neither log nor
square-root transformations of these scales produced normal
distributions, but given the large sample size within each
genetic cohort, parametric tests were used. To minimize the
potential effect of multiple testing on the Type I error rate, a
P value of <0.01 was regarded as statistically significant.
Univariate analysis was used to examine if there were any
measurable differences at baseline between BRCA1 mutation
carriers, BRCA2 mutation carriers and controls on the
dependent variables risk perception, HRQoL (SF-36), the
psychological measures (HADS, IES, MAX-PC) or knowledge.
As UK participants made up the largest proportion of
participants, a UK dataset was used as a normative
comparator for HRQoL, by randomly selecting individuals
matched to our sample on age. Means were then compared
using a paired Student’s t-test [34]. Only those aged up to
64 years were recruited to this large population-based study
therefore we limited the analysis to men aged 40–64 years
from the IMPACT cohort for the comparison.
The impact of other variables on psychosocial outcomes was
also explored. Independent variables included demographics
(age, employment status and education), prior PSA screening,
family history of PCa, time since genetic testing, and
comorbidities coded from clinical interview into a Charlson
Comorbidity Index score [40]. Knowledge of genetics and
PCa and risk perception were also included as independent
variables, to examine their impact on psychosocial outcomes.
The associations were investigated initially with ANOVA,
Student’s t-tests, chi-squared tests and Pearson’s
correlations, as appropriate. For categorical independent
variables, strength of association was calculated with
Cohen’s d for any significant relationship. Subsequently,
multivariate linear regression analyses were performed
employing all independent variables found to be associated
significantly at the univariate level with a psychosocial
outcome.
Results
Sample Characteristics and Response Rate
Of the 65 centres participating in the IMPACT study, 23
agreed to take part in the HRQoL sub-study, including all 19
UK centres, two in Spain and two in the USA. The main
reasons for electing not to participate as a centre were
financial; there was no specific funding to support this sub-
study at collaborating sites outside of the UK. A total of 780
men enrolled in the HRQoL study, of whom 476 enrolled
prior to their first screening visit (prospective cohort,
reported in the present paper). This corresponds to 26% of
the participants in the IMPACT study taking part in this sub-
study. Those who returned their questionnaire >1 month
True False
1. One-half of all cases of prostate cancer are caused by BRCA1/2 
mutations.
2. A father can pass BRCA1/2 mutations to his daughters.
3. About one in 10 men have an altered BRCA1/2 gene.
4. There are many different genes that cause prostate cancer.
5. A man with an altered BRCA1/2 gene has a 50% chance of 
passing it to each of his children.
6. Even if a man does not have an altered BRCA1/2 gene, his 
children can get it from their grandmother / grandfather (his 
parents) i.e. the gene alteration can skip generations.
7. If a man carries a gene mutation associated with prostate 
cancer, he will always develop prostate cancer at some point 
during his lifetime.
8. If a man does not carry a gene mutation associated with 
prostate cancer, he will not develop prostate cancer.
9. Every man who has been diagnosed with prostate cancer carries 
a gene mutation associated with prostate cancer.
Fig. 1 Knowledge questionnaire.
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after their initial screening visit or had not returned the study
consent form were excluded (n = 35), as were nine men who
were untested for their familial mutation, remaining at 50%
risk. The data presented are therefore from 432 men, 351 of
whom were recruited in the UK, 50 from the USA and 31
from Spain. No significant differences in responses were
observed between nationalities.
Uptake into the HRQoL sub-study was 85–100% at
participating sites. There was no significant difference in the
participants’ sociodemographics (employment status or
education) between the men in this sub-study and those in
the parent IMPACT study.
In all, 98 men (22.7%) carried a mutation in the BRCA1 gene,
160 (37.0%) carried a mutation in the BRCA2 gene and 174
(40.3%) were controls. The median time from undergoing
genetic testing to joining the IMPACT study was 7.2 months
(range 0 months–15.4 years); 47.4% of men joined within
6 months of testing, and 39.6% of men had had at least one
PSA measurement before they joined the IMPACT study.
The sociodemographic characteristics and family cancer
history of the cohort are shown in Table 1. The mean age of
the men when they completed the baseline questionnaire was
53.1 years. The majority were white (98.9%) and in higher
managerial or professional occupations (55.3%), and
employment and educations levels were similar to the UK
general population, with 4.4% unemployed and 37.7% having
college degrees or postgraduate qualifications [41,42].
Risk Perception and Knowledge
Participants’ perception of their lifetime risk of PCa was
influenced significantly by their carrier status (P < 0.001;
Table 2). BRCA2 mutation carriers were more likely to rate
their risk of PCa as moderately or strongly increased
compared with the general population than the control
group.
Knowledge scores were not affected by the genetic status of
the participant, time since genetic testing or education level.
Family history of PCa, education level, time since genetic
testing and age were not significantly associated with any of
the outcome variables.
SF-36 Questionnaire
Overall physical functioning SF-36 scores did not differ
significantly from the normative sample (IMPACT sample
aged 40–64 years mean score: 48.1; matched normative
sample mean score: 47.5; P = 0.52). The overall mental
functioning SF-36 score was significantly better in the study
cohort compared with the normative sample, but the effect
size was small and both mean values were close to the
standardized mean of 50 (IMPACT sample aged 40–64 years
mean score: 52.0; matched normative sample mean score:
49.8; P = 0.008, Cohen’s d = 0.21). Means also did not differ
significantly across genetic groups.
HADS Questionnaire
The overall mean anxiety and depression scores for the
HADS were 4.9 and 2.8, respectively, which were not higher
than previously reported general population norms [43]. The
means across different genetic risk groups also did not differ
significantly (Table 2; anxiety: P = 0.99; depression: P = 0.75).
None of the independent variables showed a significant
association with either the anxiety or depression scores.
Those with higher risk perception had slightly higher scores
on the anxiety and depression scales (P = 0.02 and P = 0.03,
respectively; Table 3), although the difference was not
clinically significant.
IES, CWS, MAX-PC Questionnaires
At the univariate level, the mean intrusion and avoidance
scores on the IES scale were significantly higher in both
BRCA1 and BRCA2 mutation carriers compared with controls
(intrusion: P = 0.001; avoidance: P < 0.001; Table 2) and
higher in those who perceived their PCa risk as moderately
or strongly increased (intrusion: P < 0.001, avoidance: P =
0.001; Table 3); however, at the multivariate level, risk
perception contributed more significantly to the variation in
IES scores than genetic status (Table 4).
A similar pattern was seen for the cancer worry score. Scores
were generally low and univariately associated with genetic
status (CWS-R: P = 0.004; Table 2) and risk perception
(CWS: P < 0.001; Table 3). Again, risk perception was more
Table 1 Sociodemographic characteristics of the cohort.
n %
Education 415 96.1
Pre-high school 108 25.0
High school or technical 144 33.3
Degree or postgraduate 163 37.7
Employment 429 99.3
In active paid work 328 75.9
Retired 82 19.0
Unemployed 19 4.4
Family history of prostate cancer 432 100
None 293 67.8
In ≥1 first degree relative 139 32.2
Time since genetic testing 424 98.1
0–3 months prior to enrolment 125 28.9
3–6 months 76 17.6
6–12 months 48 11.1
12–24 months 49 11.3
2–5 years 76 17.6
>5 years 50 11.6
Age Mean: 53.1; Median: 53.0 SD: 8.5
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highly associated with higher cancer worry than genetic status
in the multivariate model (Table 4).
Scores for PCa anxiety (MAX-PC) were only associated with
risk perception (P < 0.001), therefore, a multivariate analysis
was not undertaken.
Discussion
This study investigated the baseline HRQoL and psychosocial
profiles of men taking part in the IMPACT study, prior to
their first screening appointment. The results indicate that
participants, in general, do not have clinically concerning
levels of general or cancer-specific distress (i.e. indicative of
the presence of clinical depression or anxiety) or poor
HRQoL. A small subset of participants had higher levels of
distress, but perception of risk contributed more to explaining
the variance in distress level than did genetic status. General
population screening studies in the UK and European series
have reported similar findings: that PCa screening does not
have a detrimental effect on measures of HRQoL and
psychological health [28,44,45].
It was reassuring that participants’ perceptions of PCa risk
were influenced by carrier status, largely reflecting what
would have been communicated during genetic counselling
[2,3]. As expected, BRCA2 mutation carriers had the highest
perceived risk of PCa, most frequently classifying risk as
Table 2 Descriptive statistics and summary of group comparisons for the psychosocial variables.
Scale Scale range /
threshold
Overall BRCA1 mutation
carriers
BRCA2 mutation
carriers
Controls Cohen’s d*
N Mean (SD)
% above
threshold
N Mean (SD) %
above
threshold
N Mean (SD)
% above
threshold
N Mean (SD)
% above
threshold
SF-36 physical
component
summary
Range 0–100 404 47.4 (10.0) 90 46.4 (10.7) 148 47.1 (10.1) 166 48.3 (8.6)
SF-36 mental
component
summary
Range 0–100 404 52.4 (10.2) 90 52.1 (11.1) 148 51.2 (10.5) 166 53.7 (9.3)
Total
anxiety
(HADS)
Range 0–21 431 4.9 (3.6) 97 4.9 (3.5) 160 4.8 (3.8) 174 4.9 (3.4)
Abnormal
threshold
≥11 28 6.5% 6 6.2% 12 7.5% 10 5.7%
Total
depression
(HADS)
Range 0–21 431 2.8 (3.0) 97 2.9 (3.2) 160 2.9 (3.1) 174 2.7 (2.7)
Abnormal
threshold
≥11 9 2.1% 3 3.1% 4 2.5% 2 1.1%
Total
intrusion
(IES)
Range 0–35 423 2.3 (4.9) 94 3.0† (5.7) 158 3.1† (5.5) 171 1.3† (3.5) 0.02; 0.35; 0.38
Abnormal
threshold
≥19 12 2.8% 4 4.3% 6 3.8% 2 1.2%
Total
avoidance
(IES)
Range 0–40 418 4.3 (7.0) 93 6.0† (8.4) 156 5.1† (7.4) 169 2.6† (5.2) 0.11; 0.48; 0.39
Abnormal
threshold
≥19 32 7.7% 12 12.9% 15 9.6% 5 3.0%
Total
MAX-PC
Range 0-33 420 3.5 (5.4) 94 4.1 (5.5) 156 3.9 (6.2) 170 2.8 (4.6)
Total cancer
worry
Range 4–24 430 9.5 (2.5) 97 9.7† (2.7) 160 9.9† (2.7) 173 9.1† (2.0) 0.09; 0.25; 0.36
Risk
perception
423 N/A 91 N/A 156 N/A 171 N/A
Moderately
or strongly
increased
133 31.4% 31 32.3%‡ 86 55.1%‡ 16 9.4%‡ 0.43§
Total
knowledge
score
Range 0–9 404 7.1 (1.7) 92 6.9 (1.8) 151 7.2 (1.6) 161 7.1 (1.7)
HADS, Hospital Anxiety and Depression Scale; IES, Impact of Event Scale; MAX-PC, Memorial Anxiety Scale for Prostate Cancer; SF-36, 36-item short-form health survey.
*Cohen’s d values are listed comparing BRCA1 mutation carriers with BRCA2 mutation carriers; BRCA1 mutation carriers with controls; BRCA2 mutation carriers with controls.
†P < 0.01 using ANOVA. ‡P < 0.01 using a chi-squared test for independence. §Cramer’s V test for nominal association. Bold font indicates statistically significant values.
Table 3 Means of psychosocial scales according to risk perception
categories.
Scale (mean
scores)
Risk perception P Cohen’s d
Not or
slightly
increased
Moderately/
strongly
increased
HADS anxiety 4.54 5.43 0.02
HADS depression 2.55 3.23 0.03
IES intrusion 1.33 4.42 <0.001 0.57
IES avoidance 3.32 6.11 0.001 0.39
MAX-PC (PCa) 2.62 5.32 <0.001 0.47
CWS-R 8.89 10.84 <0.001 0.76
CWS-R, Cancer Worry Scale-Revised; HADS, Hospital Anxiety and Depression Scale;
IES, Impact of Event Scale; MAX-PC, Memorial Anxiety Scale for Prostate Cancer;
PCa, prostate cancer; SF-36, 36-item short-form health survey.
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‘slightly’ or ‘moderately’ increased, and controls most
frequently classifying risk as the ‘same’ as the general
population.
Knowledge levels were high across the cohorts, irrespective of
genetic status, education level and time since testing, showing
that men retained accurate information about inheritance of
BRCA1/BRCA2 mutations and cancer risk. The knowledge
questionnaire was designed specifically for this study, but was
adapted from that used in other studies [37,38]. These studies
reported knowledge levels to be ~50% in women at risk of
breast cancer prior to BRCA1/BRCA2 testing. The high levels
of knowledge reported in our cohort could reflect that they
have recently revisited their risk status in making a decision
to undergo screening in the IMPACT study; however, men
were asked to complete these questionnaires prior to their
first screening appointment and so may not have had a
detailed discussion about risk of PCa since being informed
about their genetic status.
The sociodemographic characteristics of the cohort indicate
that employment and education levels are similar to those
observed in the UK general population [41,42]; however,
participants were predominantly white, which is not
representative of the general UK population, and therefore
caution should be exercised in generalizing these results to
other ethnic groups.
The HRQoL assessments did not detect any clinically relevant
differences in either physical or mental health when
compared with general population samples, both matched
and unmatched by age [34]. Our results support those of the
Finnish European Randomized Screening for Prostate Cancer
study cohort in which HRQoL was also assessed with the SF-
36 [45]. As in our cohort, HRQoL scores were observed to be
higher than in the general Finnish population [45], but not at
clinically significant levels; this was hypothesized to be
because the men were generally healthy and well educated;
however the Finnish cohort was not age-matched, which may
have conferred some bias.
In terms of general distress, scores were within previously
reported population norms [43] and no differences were
observed between mutation carriers and controls. For cancer-
specific distress, a significant difference was found between
BRCA mutation carriers and controls for both the IES and
CWS; however the differences were small and mean scores
remained below clinically relevant levels for the IES.
Importantly, at the multivariate level, risk perception was
found to have a stronger association with distress levels than
genetic status itself.
No significant association was observed between anxiety and
having a family history of PCa, supporting previous reports
[15,24,28,44,46]. Men reporting higher PCa risk perception
were found to have consistently higher scores across all
psychological distress scales (general and cancer-specific).
Similar results were reported by Taylor et al. [24]; however, the
effect size was small across all scales and no group had a mean
distress score that reached clinically significant levels, where
such thresholds were available [30,43]. It is therefore fair to
conclude that, whilst having a modest impact on men’s distress
levels, a high perceived PCa risk is not associated strongly with
clinically significant levels of distress in this cohort.
A number of studies have reported that anxiety about cancer
screening affects a small number of people who are
predisposed to anxiety, and that this anxiety continues
throughout participation in cancer screening [16,27,28,44,47].
Our data support this finding, with a small proportion of
men reporting clinically significant levels of distress. It will be
important to compare these baseline levels with subsequent
screening rounds in the IMPACT study and to include
previous high PSA results as a covariate, as both the
European and US screening studies report high levels of
anxiety in men with previously elevated PSA levels [26,27].
Identifying men with a predisposition to high levels of
psychological distress could facilitate providing timely support
to manage this distress and potentially increase adherence to
screening recommendations.
Table 4 Results of multivariable linear regression analysis for the Hospital Anxiety and Depression Scale, Impact of Events Intrusion and Avoidance, and
Cancer Worry Scale-Revised.
Variables B SE T P R2 R2 change
IES intrusion Risk perception 2.92 0.55 5.32 <0.001 0.087 0.087
BRCA2 status 0.42 0.58 0.72 0.47 0.087 0.000
BRCA1 status 0.98 0.62 1.59 0.11 0.092 0.006
IES avoidance Risk perception 2.18 0.81 2.70 0.007 0.058 0.017
BRCA2 status 1.50 0.85 1.76 0.08 0.042 0.025
BRCA1 status 2.88 0.91 3.18 0.002 0.017 0.017
CWS-R Risk perception 1.98 0.27 7.46 <0.001 0.137 0.137
BRCA2 status –0.07 0.28 –0.24 0.81 0.138 0.001
BRCA1 status 0.14 0.30 0.47 0.64 0.138 0.000
CWS-R, Cancer Worry Scale-Revised; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Event Scale. Variables included represent those significant on the univariate
level.
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We did not observe a significant association between distress
and age. While this supports several earlier studies [16,44],
one study reported an inverse relationship between age and
distress levels [27].
It is important to consider whether we would have observed
different results if all men in the IMPACT study had been
included in this psychosocial sub-study; however we found
no difference in sociodemographic characteristics between
the men in the sub-study and those in the IMPACT study
as a whole. It could be that those more predisposed to
anxiety may be inclined not to join the psychosocial sub-
study; however, no evidence of this has been found by
others [28].
We obtained a very high uptake level for the psychosocial
sub-study, with at least 85% opting in at participating sites.
Uptake was also found to be high in the European
Randomized study of Screening for Prostate Cancer Swedish
cohort, with 84–94% of men with abnormal PSA levels
completing a questionnaire measuring anxiety levels [27]. The
high participation rate is probably attributable to the
embedding of this psychosocial study into an existing
screening study, and therefore inviting participants who are
already highly motivated to contribute to research.
A strength of the present study is the use of a number of
different, standardized psychological measures that offer
extensive insight into the psychosocial profile of the
participants and that allow comparison of the results with a
number of other PCa screening studies that have used the
same or similar measures.
It should be noted that our sample was restricted to men who
have previously engaged with health services by undergoing
genetic testing and who responded positively to an invitation
to take part in a research study. In addition, there was limited
variability in ethnicity, which may limit the generalizablity of
the findings to other populations.
The data presented represent a snapshot of men’s
psychosocial profiles when they joined the IMPACT study.
Follow-up data will inform whether the PCa screening
process has an impact on HRQoL or distress over time.
To the best of our knowledge, this is the first study to
report the psychosocial and HRQoL profile of men with
BRCA1/BRCA2 mutations taking part in a PCa screening
study. Uptake into the study was very high, and
participants had very high levels of knowledge about
genetics and PCa. As a whole, the cohort did not
demonstrate any clinically concerning levels of general or
cancer-specific distress or poor HRQoL. A small subset of
participants reported higher levels of distress, but
perception of risk was more strongly associated with
distress levels than was genetic status. It is important for
healthcare professionals who are providing PCa screening
to be aware of these predictors of distress so that men with
potential for heightened distress can be identified and
adequate counselling and support can be offered. Follow-up
data will determine whether these factors have an impact
on adherence to screening and whether men experiencing
abnormal PSA results experience more distress.
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